A phase II trial of ZP 4207 as a multiple-dose use for the correction of mild to moderate hypoglycemia

Trial Profile

A phase II trial of ZP 4207 as a multiple-dose use for the correction of mild to moderate hypoglycemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Dasiglucagon (Primary)
  • Indications Hypoglycaemia; Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 17 May 2017 Status changed from planning to recruiting, as reported in a Zealand Pharma media release.
    • 17 May 2017 According to Zealand Pharma media release, results from this trial are expected in this quarter.
    • 10 Jun 2016 According to Zealand Pharma media release, company plans to enroll the first patient with type 1 diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top